Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M149Revenue (TTM) $M175Net Margin (%)71.9Altman Z-Score-29.6
Enterprise Value $M275EPS (TTM) $1.2Operating Margin %38.5Piotroski F-Score4
P/E(ttm)1.3Beneish M-Score4,456Pre-tax Margin (%)71.9Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio0.8Cash flow > EarningsN
Price/Sales0.95-y EBITDA Growth Rate %--Current Ratio0.8Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)112Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M95.8ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with MNKD

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

MNKD is held by these investors:



MNKD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PFEFFER MATTHEW JCEO, CFO, Director 2017-01-03Buy908$2.7-42.22view
Alinaya Rosabel RealicaSVP, Prin Acctg Officer 2017-01-03Buy1,809$2.7-42.22view
Castagna MichaelChief Commercial Officer 2016-08-26Buy3,500$3.9-60view
Castagna MichaelChief Commercial Officer 2016-08-24Buy3,000$4.35-64.14view
Castagna MichaelChief Commercial Officer 2016-08-23Buy5,000$4.7-66.81view
PFEFFER MATTHEW JCEO, CFO, Director 2016-08-15Buy5,000$4.95-68.48view
Castagna MichaelChief Commercial Officer 2016-08-12Buy5,000$5-68.8view
Alinaya Rosabel RealicaSVP, Prin Acctg Officer 2016-07-06Sell1,259$5.3-70.57view
Castagna MichaelChief Commercial Officer 2016-05-17Buy10,000$4.65-66.45view
Martens JuergenCorporate VP and COO 2015-05-21Buy4,000$22.85-93.17view

Press Releases about MNKD :

Quarterly/Annual Reports about MNKD:

News about MNKD:

Articles On GuruFocus.com
Why MannKind Could Be a Value Trap Jan 04 2016 
MannKind Corporation Disappoints with Afrezza Sales; Analysts Lower Expectations May 11 2015 
MannKind Looks Good For Long Term Investors Apr 29 2015 
Analysts Weigh in on MannKind Following Q4 Results Feb 27 2015 
What to Watch for: November 3-7 Nov 04 2014 
Roche to Acquire InterMune and Deliver Hope to Patients Worldwide Aug 25 2014 
How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
Evaluating MannKind (MNKD) & Sanofi (SNY) Agreement for Afrezza Aug 15 2014 
There is a Tide in the Affairs of MannKind: When Taken At the Flood, Will Lead to Fortune Aug 14 2014 

More From Other Websites
MANNKIND CORP Financials Mar 23 2017
Jefferies Has 4 Red-Hot Biotech and Pharmaceutical Stocks to Buy Now Mar 20 2017
MANNKIND CORP Files SEC form 8-K, Other Events Mar 17 2017
Edited Transcript of MNKD earnings conference call or presentation 16-Mar-17 9:00pm GMT Mar 17 2017
MannKind posts 4Q profit Mar 16 2017
MannKind posts 4Q profit Mar 16 2017
MANNKIND CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 16 2017
MannKind Corporation Reports 2016 Fourth Quarter and Full Year Financial Results Mar 16 2017
When Profit Makers Can Be Active Profit Takers Mar 16 2017
Q4 2016 MannKind Corp Earnings Release - Before Market Open Mar 16 2017
Top 10 Long/Short Estimize Signal Scores [Week 3/13] Mar 14 2017
Major Biotechs See a Retreat in Short Interest Mar 10 2017
The 6 Most Shorted Nasdaq Stocks Mar 10 2017
MannKind Corporation and Charles Mattocks Announce “REVERSED”-America’s First Docu-Series... Mar 08 2017
MannKind Corporation Announces Upcoming Events Mar 07 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)